checkAd

     104  0 Kommentare Flexion Therapeutics to Advance Investigational Gene Therapy FX201 into High Dose Cohort of Phase 1 Clinical Trial in Knee Osteoarthritis and Expand Low and Mid Dose Treatment Groups - Seite 3

    Contact:

    Scott Young
    Vice President, Corporate Communications & Investor Relations
    T: 781-305-7194
    syoung@flexiontherapeutics.com

    Lesen Sie auch

    Julie Downs
    Associate Director, Corporate Communications & Investor Relations
    T: 781-305-7137
    jdowns@flexiontherapeutics.com 



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Flexion Therapeutics to Advance Investigational Gene Therapy FX201 into High Dose Cohort of Phase 1 Clinical Trial in Knee Osteoarthritis and Expand Low and Mid Dose Treatment Groups - Seite 3 First-in-human single ascending dose trial advances to high dose cohort following positive Data Monitoring Committee review of mid dose safety dataCompany to expand FX201 low dose and mid dose cohorts to include up to 20 additional patients in each …